Novonesis A/s Class B · OMXCOP:NSIS_B
Novonesis A/s Class B — 9M 2021 Earnings Presentation
12 slides from Novonesis A/s Class B's earnings presentation, Oct 27, 2021
Slide 1: Conference call 9M 2021
Conference call 9M 2021 October 27, 2021
Slide 2: Forward Looking Statement
Disclaimer Forward Looking Statement This presentation and its related comments contain forward-looking statements, including statements about future events, future financial performance, plans, strategies and expectations. Forward-looking statements are associated with words such as, but not limite
Slide 3: Highlights
Highlights 9M 2021 Q3 2021 Stronger performance leads to raised full-year outlook Realized Realized • Organic 9M sales growth y/y: 6% (Q3 y/y: 7%). Sales performance, organic % 6 7 • Well-diversified exposure with double-digit organic sales growth in three of the five EBIT margin % 28.8 29.1 busines
Slide 4: Household Care
Household Care Solid performance in EM and Freshness platform; Europe softer 2021 perspectives than expected • Enzyme penetration in emerging markets. • Organic 9M sales growth y/y: 0% (Q3 y/y: 3%). • Freshness rollout with broad market launch. • Performance mainly driven by increased enzymatic • Eu
Slide 5: Food, Beverages & Human Health
Food, Beverages & Human Health Strong performance above expectations 2021 perspectives • Organic 9M sales growth y/y: 15% (Q3 y/y: 16%). • Food performance driven by innovation, emerging markets • Strong performance above expectations; all subareas growing penetration, health-focused solutions and s
Slide 6: Bioenergy
Bioenergy Strong performance on a COVID-19 impacted baseline 2021 perspectives • Organic 9M sales growth y/y: 12% (Q3 y/y: 5%). • Growth driven by gradual recovery in U.S. ethanol • Strong 9M performance driven by recovery in U.S. ethanol production, capacity expansion in Latin America, and volumes
Slide 7: Grain & Tech Processing
Grain & Tech Processing Broad-based growth outperforming expectations 2021 perspectives • Organic 9M sales growth y/y: 12% (Q3 y/y: 4%). • Growth expected across most subareas. • Strong 9M performance outperforming expectations; both • Innovation and market penetration driving growth in grain and te
Slide 8: Agriculture, Animal Health & Nutrition
Agriculture, Animal Health & Nutrition Solid growth in line with expectations 2021 perspectives • Organic 9M sales growth y/y: -3% (Q3 y/y: 16%). • Full-year organic sales indication of low single-digit • Decline as expected due to negative base effect from BioAg growth. one-off and difficult compar
Slide 9: Financials – 9M performance
Financials – 9M performance Strong and better-than-expected performance across sales, earnings and cash flows • 9M organic sales growth y/y: 6%; DKK sales 5% y/y. • Gross margin strong at 58.2%; 200bps higher than last year, driven by production efficiencies and productivity improvements. • Strong E
Slide 10: Outlook 2021
Outlook 2021 Full-year outlook raised after stronger-than-expected performance • Organic sales growth of 5% to 6% with sales in reported DKK roughly on par. • EBIT margin at around 27%. • ROIC incl. goodwill at 20% to 21%. • Free cash flow before acquisitions at DKK 2.8bn to 3.2 billion. 2021 outloo
Slide 11: Summary
Summary Stronger performance leads to increased full-year outlook • Execution of strategic direction in focus – with clear emphasis on prioritization. • Investing for the long term while delivering in the shorter term. • Sustainability as an enabler of growth; COP26 meeting in November engaging comp
Slide 12: Slide 12